Literature DB >> 22131030

Control of the interferon response in RNAi experiments.

Jana Nejepinska1, Matyas Flemr, Petr Svoboda.   

Abstract

The RNA interference (RNAi) and interferons have been an uneasy marriage. Ever since the discovery of RNAi in mammals, the interferon response has been a feared problem. While RNAi became an efficient and widespread method for gene silencing in mammals, numerous studies recognized several obstacles, including undesirable activation of the interferon response, which need to be overcome to achieve a specific and robust RNAi effect. The aim of this text is to provide theoretical and practical information for scientists who want to control interferon response and other adverse effects in their RNAi experiments.

Mesh:

Substances:

Year:  2012        PMID: 22131030     DOI: 10.1007/978-1-61779-439-1_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  RFWD3-Dependent Ubiquitination of RPA Regulates Repair at Stalled Replication Forks.

Authors:  Andrew E H Elia; David C Wang; Nicholas A Willis; Alexander P Boardman; Ildiko Hajdu; Richard O Adeyemi; Elizabeth Lowry; Steven P Gygi; Ralph Scully; Stephen J Elledge
Journal:  Mol Cell       Date:  2015-10-15       Impact factor: 17.970

2.  RNA interference approaches for treatment of HIV-1 infection.

Authors:  Maggie L Bobbin; John C Burnett; John J Rossi
Journal:  Genome Med       Date:  2015-05-28       Impact factor: 11.117

Review 3.  A CRISPR View of Biological Mechanisms.

Authors:  Eduardo Martinez; Lilia Sanchez; Neftali Vazquez; Rebecca Marks; Raechel Cedillo; Christa Respondek; Martin Holguin; Michael W Persans; Megan Keniry
Journal:  Discoveries (Craiova)       Date:  2016-12-31

4.  Therapeutic siRNAs Targeting the JAK/STAT Signalling Pathway in Inflammatory Bowel Diseases.

Authors:  Flora Clément; Adrien Nougarède; Stéphanie Combe; Frédérique Kermarrec; Arindam K Dey; Patricia Obeid; Arnaud Millet; Fabrice P Navarro; Patrice N Marche; Eric Sulpice; Xavier Gidrol
Journal:  J Crohns Colitis       Date:  2022-02-23       Impact factor: 9.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.